Table 2.
Hospital course and treatment outcomes.
| Variables | All Patients (n = 63) |
|---|---|
| Clinical improvement | |
| Day-7 clinical improvement | 42 (66.7%) |
| Patients who did not require O2 supplementation (n = 27) | 25 (92.6%) |
| Patients who required O2 supplementation (n = 36) | 17 (47.2%) |
| Day-14 clinical improvement | 54 (85.7%) |
| Patients who did not require O2 supplementation (n = 27) | 27 (100.0%) |
| Patients who required O2 supplementation (n = 36) | 27 (75.0%) |
| Day-28 clinical improvement | 57 (90.5%) |
| Patients who did not require O2 supplementation (n = 27) | 27 (100.0%) |
| Patients who required O2 supplementation (n = 36) | 30 (83.3%) |
| ICU duration, median (range), day | 0 (0–46) |
| Required IMV * or ECMO ** during hospitalization | 8 (12.7%) |
| Required IMV * or ECMO ** before initiation of favipiravir | 4 (6.3%) |
| Required IMV * or ECMO ** after initiation of favipiravir | 4 (6.3%) |
| 14-day mortality rate | 1 (1.6%) |
| 28-day mortality rate | 3 (4.8%) |
| In-hospital mortality rate | 5 (7.9%) |
| Length of hospital stay, median (range), day | 15 (2–47) |
| Adverse drug reactions | 39 (61.9%) |
| Diarrhea | 34 (54.0%) |
| Hepatitis | 4 (6.4%) |
| QT interval prolongation | 4 (6.4%) |
| Nausea and vomiting | 5 (7.9%) |
| Superimposed bacterial infection | 8 (12.7%) |
Note. * IMV: invasive mechanical ventilation; ** ECMO: extracorporeal membrane oxygenation.